The first Phase III data for Novartis' Exforge (amlodipine besylate/valsartan) showed patients with high blood pressure treated with the investigational medicine experienced strong reductions of blood pressure with excellent tolerability.
The data also showed that the two complementary mechanisms of action helped more than 80 percent of patients studied reach their recommended blood pressure goals. Exforge was shown to be safe and well-tolerated in the overall clinical trial program involving 5,000 patients.
